Northern Trust Corp Has $27.54 Million Holdings in Amicus Therapeutics, Inc. $FOLD

Northern Trust Corp lifted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 0.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,375,126 shares of the biopharmaceutical company’s stock after acquiring an additional 3,487 shares during the quarter. Northern Trust Corp owned approximately 1.10% of Amicus Therapeutics worth $27,541,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the stock. Algert Global LLC raised its position in Amicus Therapeutics by 92.9% in the 1st quarter. Algert Global LLC now owns 820,026 shares of the biopharmaceutical company’s stock worth $6,691,000 after purchasing an additional 394,943 shares during the last quarter. Aberdeen Group plc raised its position in Amicus Therapeutics by 14.9% in the 1st quarter. Aberdeen Group plc now owns 1,586,609 shares of the biopharmaceutical company’s stock worth $12,947,000 after purchasing an additional 205,834 shares during the last quarter. Sei Investments Co. raised its position in Amicus Therapeutics by 2.7% in the 1st quarter. Sei Investments Co. now owns 224,932 shares of the biopharmaceutical company’s stock worth $1,835,000 after purchasing an additional 6,018 shares during the last quarter. Russell Investments Group Ltd. raised its position in Amicus Therapeutics by 167.6% in the 1st quarter. Russell Investments Group Ltd. now owns 142,569 shares of the biopharmaceutical company’s stock worth $1,163,000 after purchasing an additional 89,287 shares during the last quarter. Finally, Nuveen LLC bought a new position in Amicus Therapeutics in the 1st quarter worth approximately $28,741,000.

Analysts Set New Price Targets

Several research firms recently weighed in on FOLD. Wall Street Zen cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday. Morgan Stanley upgraded shares of Amicus Therapeutics from an “equal weight” rating to an “overweight” rating in a research report on Thursday, July 17th. Eight investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $16.22.

Amicus Therapeutics Stock Performance

Shares of Amicus Therapeutics stock opened at $7.59 on Friday. The firm has a fifty day moving average of $6.53 and a two-hundred day moving average of $7.11. The stock has a market capitalization of $2.34 billion, a price-to-earnings ratio of -63.24 and a beta of 0.53. Amicus Therapeutics, Inc. has a 52 week low of $5.51 and a 52 week high of $12.65. The company has a debt-to-equity ratio of 1.92, a quick ratio of 2.29 and a current ratio of 3.21.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.